Literature DB >> 8786047

Epidemiology of hepatitis B infection in the Western Pacific and South East Asia.

I D Gust1.   

Abstract

The Western Pacific and South East Asia regions are the largest and most populous of the six World Health Organisation regions and include more than 40 countries. More than 75% of the world's estimated 350 million carriers are located here. The region has therefore provided many insights into the epidemiology, natural history, and control of hepatitis B infection and has been home to the first national control programmes. Hepatitis B is hyperendemic in most countries of the region, with carrier rates ranging from 5-35% except in Australia, New Zealand, and Japan, where the mean carrier rate is less than 2%. Patterns of infection vary considerably from country to country, city to city, and even village to village, and can change with time. Most infections are acquired early in childhood or in early adult life. A variety of control measures are in place and many countries in the region have introduced widespread or universal childhood immunisation policies with significant success. While it is theoretically possible that hepatitis B infection could be eradicated by universal childhood immunisation, there are several biological and practical issues that make this extremely difficult, suggesting that, for the foreseeable future, control may be a more realisable goal.

Entities:  

Mesh:

Year:  1996        PMID: 8786047      PMCID: PMC1398038          DOI: 10.1136/gut.38.suppl_2.s18

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  28 in total

1.  A "NEW" ANTIGEN IN LEUKEMIA SERA.

Authors:  B S BLUMBERG; H J ALTER; S VISNICH
Journal:  JAMA       Date:  1965-02-15       Impact factor: 56.272

2.  Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.

Authors:  R P Beasley; L Y Hwang; C C Lin; C S Chien
Journal:  Lancet       Date:  1981-11-21       Impact factor: 79.321

3.  Hepatitis B immune globulin (HBIG) efficacy in the interruption of perinatal transmission of hepatitis B virus carrier state. Initial report of a randomised double-blind placebo-controlled trial.

Authors:  R P Beasley; L Y Hwang; C C Lin; C E Stevens; K Y Wang; T S Sun; F J Hsieh; W Szmuness
Journal:  Lancet       Date:  1981-08-22       Impact factor: 79.321

4.  Studies on hepatitis B surface antigen and antibody in Nauru. II. Distribution amongst Gilbert and Ellice (Tuvalu) islanders.

Authors:  I D Gust; M Dimitrakakis; F Bott; P Zimmet
Journal:  Am J Trop Med Hyg       Date:  1978-11       Impact factor: 2.345

5.  A prospective study on the development of hepatocellular carcinoma from liver cirrhosis with persistent hepatitis B virus infection.

Authors:  H Obata; N Hayashi; Y Motoike; T Hisamitsu; H Okuda; S Kobayashi; K Nishioka
Journal:  Int J Cancer       Date:  1980-06-15       Impact factor: 7.396

6.  Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine.

Authors:  R P Beasley; L Y Hwang; G C Lee; C C Lan; C H Roan; F Y Huang; C L Chen
Journal:  Lancet       Date:  1983-11-12       Impact factor: 79.321

7.  Seroepidemiology of infection with hepatitis A and B viruses in an isolated Pacific population.

Authors:  I D Gust; N I Lehmann; M Dimitrakakis; P Zimmet
Journal:  J Infect Dis       Date:  1979-05       Impact factor: 5.226

8.  Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial.

Authors:  R P Beasley; L Y Hwang; C E Stevens; C C Lin; F J Hsieh; K Y Wang; T S Sun; W Szmuness
Journal:  Hepatology       Date:  1983 Mar-Apr       Impact factor: 17.425

9.  Studies on hepatitis B surface antigen and antibody in Nauru. I. Distribution amongst Nauruans.

Authors:  I D Gust; M Dimitrakakis; P Zimmet
Journal:  Am J Trop Med Hyg       Date:  1978-09       Impact factor: 2.345

10.  Seroepidemiology of infection with hepatitis B virus in Fiji.

Authors:  H Zhuang; A G Coulepis; P Zimmet; R Taylor; P Ram; S Banuve; I D Gust
Journal:  Am J Epidemiol       Date:  1982-10       Impact factor: 4.897

View more
  40 in total

1.  Hepatitis B prevention and control: Lessons from the East and the West.

Authors:  Monica C Robotin
Journal:  World J Hepatol       Date:  2011-02-27

Review 2.  Hepatitis B virus epidemiology.

Authors:  Jennifer H MacLachlan; Benjamin C Cowie
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

3.  Recombination in the genesis and evolution of hepatitis B virus genotypes.

Authors:  Peter Simmonds; Sofie Midgley
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.

Authors:  Chun-Jen Liu; Pei-Jer Chen; Ding-Shinn Chen; Jia-Horng Kao
Journal:  Hepatol Int       Date:  2011-06-14       Impact factor: 6.047

Review 5.  Natural history of chronic hepatitis B: phases in a complex relationship.

Authors:  Catherine M N Croagh; John S Lubel
Journal:  World J Gastroenterol       Date:  2014-08-14       Impact factor: 5.742

6.  Low level of Hepatitis B knowledge and awareness among pregnant women in the Kintampo North Municipality: implications for effective disease control.

Authors:  Martha Ali Abdulai; Frank Baiden; George Adjei; Seth Owusu-Agyei
Journal:  Ghana Med J       Date:  2016-09

Review 7.  Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy.

Authors:  Dede Sit; Bennur Esen; Ahmet Engin Atay; Hasan Kayabaşı
Journal:  World J Hepatol       Date:  2015-04-18

8.  Hepatitis B control by 2012 in the WHO Western Pacific Region: rationale and implications.

Authors:  Manju Rani; Baoping Yang; Richard Nesbit
Journal:  Bull World Health Organ       Date:  2009-09       Impact factor: 9.408

9.  Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment.

Authors:  Yan Liu; Felicia Wu
Journal:  Environ Health Perspect       Date:  2010-02-19       Impact factor: 9.031

Review 10.  Lamivudine: in children and adolescents with chronic hepatitis B virus infection.

Authors:  Susan J Keam; Lesley J Scott
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.